BOSTON--(BUSINESS WIRE)--Velsera, a global healthcare technology company that offers leading biomedical data analysis platforms, has joined forces with Flywheel, the leading medical imaging management and artificial intelligence (AI) development platform, and the Center for Data-Driven Discovery in Biomedicine (D3b) based at Children’s Hospital of Philadelphia, to advance the analysis of large-scale genomics and medical imaging datasets. In this collaborative pilot effort through the NIH-wide INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project, the partners combined their expertise to unite the Velsera CAVATICA platform and the Flywheel Core Platform, providing unprecedented capabilities to scale multimodal data analysis with clear pathways to advance precision medicine programs across government and pharmaceutical sectors. While extensive amounts of genomic and imaging data are being amassed in the healthcare system today, researchers struggle to combine this data in ways that could help make the discovery of new treatments faster and more precise. Limitations include access obstacles, privacy concerns, and integration and computational requirements for such large datasets. Combining their capabilities, Velsera, Flywheel, and D3b were able to manage, harmonize, and analyze large datasets in a cloud-based platform.The Velsera team created interoperability standards that allow platforms to communicate with each other and make large-scale data access transparent to the user. These interoperability standards make 14 PB of data accessible from the Velsera platform ecosystem.The Flywheel platform uses containerized algorithms to de-identify images, run QC workflows, and consistently curate data to facilitate large-scale sharing and analysis of imaging data sets.The D3b team provided vision of AI and imaging data, subject matter expertise in health data and bioinformatics analysis pipelines, and, within the NIH-funded INCLUDE Data Coordinating Center and Office of Data Science Strategy, FHIR proficiency critical for data harmonization.“Linking our Flywheel Core Platform with Velsera’s CAVATICA platform facilitates an unparalleled ability to perform advanced, multimodal data analysis in a cloud environment,” said Travis Richardson, Chief Strategist at Flywheel

Computational biology company Velsera Inc. named Jamie Littlejohns CEO, succeeding interim CEO Hans Cobben, who remains chairman.

BOSTON--(BUSINESS WIRE)--Velsera, a pioneering entity in the field of computational biology with a focus on advancing precision medicine, is delighted to formally announce the appointment of Jamie Littlejohns as its Chief Executive Officer, with his tenure commencing on the 1st of March, 2024. Jamie is set to succeed Hans Cobben, who has served as the interim CEO and will revert to his position as Chairman of the Board at Velsera. Jamie joins Velsera from his previous role at McKinsey, where he was a Partner and led McKinsey’s European Healthcare Life Science Private Equity Practice. He has worked in Healthcare and Life Sciences since 2010 across Europe, the US and Australia and has developed expertise in supporting investor-backed health life science tech companies on their scale-up journeys. Although new to Velsera in a full-time capacity, Jamie has been part of Velsera’s journey since early 2022 through his support in an external advisory capacity. In his own words, Jamie says, "I am thrilled to be joining the wonderful team at Velsera